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Abstract
Background: Wegener Granulomatosis (WG) is a multifactorial disease of yet unknown aetiology
characterized by granulomata of the respiratory tract and systemic necrotizing vasculitis. Analyses
of candidate genes revealed several associations, e.g. with α(1)-antitrypsin, proteinase 3 and with
the HLA-DPB1 locus. A mutation in the abnormal limb mutant 5 (ALI5) mouse in the region coding
for the hydrophobic ridge loop 3 (HRL3) of the phospholipaseCγ2 (PLCγ-2) gene, corresponding to
human PLCγ-2 exon 27, leads to acute and chronic inflammation and granulomatosis. For that
reason, we screened exons 11, 12 and 13 coding for the hydrophobic ridge loop 1 and 2 (HRL1
and 2, respectively) and exon 27 of the PLCγ-2 protein by single strand conformation
polymorphism (SSCP), sequencing and PCR/ restriction fragment length polymorphism (RFLP)
analyses. In addition, we screened indirectly for disease association via 4 microsatellites with pooled
DNA in the PLCγ-2 gene.
Results:  Although a few polymorphisms in these distinct exons were observed, significant
differences in allele frequencies were not identified between WG patients and respective controls.
In addition, the microsatellite analyses did not reveal a significant difference between our patient
and control cohort.
Conclusion: This report does not reveal any hints for an involvement of the PLCγ-2 gene in the
pathogenesis of WG in our case-control study.
Background
Wegener granulomatosis (WG) is a systemic inflamma-
tory disease of unknown aetiology characterized by gran-
ulomata of the respiratory tract and systemic necrotizing
vasculitis [1]. There is a strong and specific association
with presence of anti-neutrophil cytoplasmatic antibodies
to a defined target antigen, proteinase 3 (PR3-ANCA),
which is present within primary azurophil granules of
neutrophils (PMN) and lysozymes of monocytes [2].
Upon cytokine priming of PMNs, this enzyme translo-
cates to the cell surface, where PR3-ANCAs can interact
with their antigens and activate PMNs [3]. It has been
shown that PMNs from patients with active WG express-
ing PR3 on their surfaces produce respiratory burst and
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release proteolytic enzymes after activation with PR3-
ANCA [4]. The consequence is a self-sustaining chronify-
ing inflammatory process. WG appears as a multifactorial
disease, and environmental influences still remain elu-
sive. Several factors, such as bacterial infections, have
been proposed as probable initiators of the disease [5]. It
has been reported that chronic carrier status of Staphyloco-
ccus aureus is a risk factor for disease exacerbation in WG
[6]. Recently a strong association of WG with distinct
HLA-DPB1  alleles or rather an extended haplotype,
respectively, in the MHC class II region has been reported
[7]. In addition, analyses of candidate genes revealed sev-
eral associations, e.g. with α(1)-antitrypsin, and protein-
ase 3 [[8] and [9]].
A primary candidate gene, PLCγ-2, was proposed on the
basis of a novel animal model system. A mutation in the
abnormal limb mutant 5 (ALI5) mouse [10] causes a phe-
notype comparable to human autoimmunity disease like
WG: inflammations, granulomatosis, affected organs
(lung, kidney with glomerulonephritis, eye and skin) and
ANCAs were detected in the ALI5 mouse initially. Yet, this
result has to be confirmed in further studies. The ALI5
mutation is located in the genomic region coding for the
hydrophobic ridge loop 3. In mouse PLCγ-2  mutation
leads to acute and chronic inflammations with a pheno-
type comparable to WG. Therefore, human PLCγ-2 is a
good candidate gene for seeking predisposing genetic fac-
tors for WG. The human gene is a member of the PLC fam-
ily comprising 12 closely related molecules involved in
signal transduction from numerous receptors [11]. The
protein is activated by cytoplasmatic tyrosine kinases
(Lyn, Syk, and Btk) which are induced by engagement of
B-cell receptors. In turn, the PLCγ-2 activation leads to the
generation of diacylglycerol (DAG) and inositol 1,4,5-tri-
sphosphat (IP3). While DAG activates protein kinase C
(PKC, [12]), IP3 mediates Ca2+ mobilization, which is
required for activation of B-cells [13]. PLCγ-2 itself is
expressed mainly in B-cell, hematopoetic cells, macro-
phages, granulocytes, testis, sperm, skin and brain [14].
The protein consists of two catalytic domains, which are
separated by two SH2 and one SH3 domains [15]. It was
established that PLCγ-2 mediates the coupling of G-pro-
tein-coupled receptors (GPCRs) and Ca2+ entry in cell
lines [16]. The human PLCγ-2 gene is localized on chro-
mosome 16 (16q24.1) spanning 179 kb of genomic DNA.
The 4.2 kb mRNA consists of 33 Exon coding for a Mr
140,000 protein with 1265 amino acids [17]. PLCγ-2 is
highly polymorphic [18].
Here, we report on an indirect association screen by mic-
rosatellite analysis and pooling of DNA in a case-control
study design. Furthermore, we screened exons 11, 12 and
13, partly coding for the hydrophobic ridge loop 1 and 2
of PLCγ-2 protein, by single stranded conformation poly-
morphism (SSCP), sequencing and the PCR/RFLP
method. As the ALI5 mutation is located in the region cor-




In the present study we analysed 4 microsatellites intra- or
juxta-genic of the PLCγ-2 gene with pooled DNAs from
WG patients compared with those from controls (table 1;
figure 1). All markers exhibited at least 3 alleles and did
not show any intra-subgroup differences. The microsatel-
lite analyses did not reveal significantly different allele
distributions between WG patient and control pools (fig-
ure 1).
SSCP, sequencing and PCR/RFLP analyses
SSCP analysis was chosen to identify mutations or poly-
morphisms, respectively, in exons 11, 12, 13 and 27 of the
PLCγ-2 gene. DNA's of patients and controls with altered
migration behaviour were sequenced. Identified varia-
tions were genotyped individually by SSCP and/or PCR/
RFLP in individual patient and control samples (see table
2). Exon 12 revealed a low frequent SNP (1122G>A),
which represents the first base pair of the exon. In exon 13
two previously identified SNPs (1293T>C and 1296T>C)
were detected [18]. Both SNPs showed similar frequencies
as reported [18]. All variations were found not signifi-
cantly different in WG patients compared to the control
Table 1: Primer sequences and information about microsatellites used in study
Primer sequence
No. sense1 antisense *nucleotide marker
1 CGCACATGTATCCAGAACT AGAGGTGGACCCATGCTTA *di (AT)
2 CAAAGAAGATAAGGGCAGGC CCTAGGCGACTCAGTGAGACT *tetra (TTTA)
3 AGGAGTTCGAGAAGAGCCTG TGCCACTACACCCAGATGAT *di (AC)
4 TGATCTGTGTCTGGGCTTTC AGTTGTGACCCTAACATTGCA *di (AC)
1 The fluorescence labelled tail (5-Fam-CATCGCTGATTCGCACAT) was added to the 5'end of each sense primerJournal of Negative Results in BioMedicine 2005, 4:1 http://www.jnrbm.com/content/4/1/1
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group, and they were not associated with amino acid sub-
stitutions. In one patient our analyses revealed a single
base substitution (3030G>A) in exon 27.
Discussion
As recently reported a mutation in the PLCγ-2 gene in the
ALI5 mouse leads to acute and chronic inflammation and
granulomatosis. In addition, the ALI5 mice show similar
symptoms as WG patients. For this reason screening of
PLCγ-2 appears as a logical consequence in seeking candi-
date genes for WG. In the present study PLCγ-2 was ana-
lysed by an indirect microsatellite approach using pooled
DNA from WG patients with a defined PR3-ANCA+ status
and a matched control cohort as reported before [7]. Fur-
thermore, exons partly representing the catalytic domains
of the PLCγ-2 protein, HRL1, 2 and 3, were analysed by
SSCP, sequencing and by the PCR/RFLP method. We did
not find any hints of an involvement of the PLCγ-2 gene
in the pathophysiology of WG. Hence, we exclude at this
time that the PLCγ-2 gene predisposes for WG in our
cohort.
Our study revealed 4 single base substitutions, 2 of which
were reported before [18]. A further silent and low fre-
quent SNP was detected in exon 12 which did not differ
significantly between patient and control cohorts after
PCR/RFLP analyses. As this SNP is the first basepair (bp)
after the 3'-splice site one might hypothesise an influence
on splicing but to present knowledge this SNP does not
change a consensus sequence required for splicing. The
ALI5 mutation is located in the HRL3 domain partly
corresponding to the human exon 27 of PLCγ-2. Our
analysis revealed a SNP (G>A) at position 3030 in one
WG patient.
Schematic representation of the human PLCγ-2 gene with relative localization of exons and investigated microsatellites Figure 1
Schematic representation of the human PLCγ-2 gene with relative localization of exons and investigated microsatellites. P val-
ues were generated by contingency tables (for details see "materials and methods"). Vertical lines: exons; No1-6: investigated 
microsatellites 1-6; Ex: exon.
Table 2: Summary of found variations in the human PLCγ-2 gene in exons 11, 12, 13 and 27
variation frequency of alleles
exon bp1 codon WG patients controls P value restriction 
enzymes
1 1 ------
12 1122G>A T329T 3/262 3/162 0.55 BanI
13 1293T>C2 F382F 7/350 4/324 0.68 PfIFI
1296T>C2 D383D 143/262 96/186 0.78 TaqI
27 3030G>A T961T 1/1663 0/1803 0.51 -
1Numbering according to BC007565 (UCSC); 2Previously reported SNPs; 3Frequencies determined by SSCP analysesJournal of Negative Results in BioMedicine 2005, 4:1 http://www.jnrbm.com/content/4/1/1
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The indirect microsatellite based approach did not reveal
any association of PLCγ-2 with WG. Altogether 4 micros-
atellites spread in the PLCγ-2 gene were analysed. The
approach using pooled DNA and ad hoc designed markers
intragenic or in the immediate vicinity of a distinct gene
has proven to be a reliable and efficient method to
detected predisposing loci in WG before [7]. Here, none of
the markers did show a significant allele distribution
between the patient and control group.
Conclusion
In conclusion, our analysis of the human PLCγ-2 gene did
not reveal an association of PLCγ-2 with WG. In contrast
to ALI5 mice, where a single mutation leads to distinct
symptoms of inflammatory autoimmunity, human WG
depends on a more complex genetic background. Further
analysis of all exons of PLCγ-2 might yield an association
with WG but our microsatellite analysis strongly suggests




175 well-characterized patients of German origin with a
clinical diagnosis of WG and a defined PR3-ANCA+ status
were included in present study. Diagnosis of WG was
established according international standards [[19] and
[20]]. All patients were biopsy-proven. Biopsies were seen
in German reference centre for vasculitis (Department of
Pathology, University of Schleswig-Holstein Campus Lue-
beck, Germany) by 2 different observers. A group of 165
healthy individuals of German origin were used as con-
trols. All persons gave informed consent.
Microsatellite analysis
Pooling of DNA was performed as reported before [7].
Patient (n = 150) and healthy control (n = 100) individu-
als from the abovementioned groups were divided into 3
and 2 sub-pools, respectively, containing 50 persons each.
In this study 3 intragenic microsatellites as well as one in
the immediate vicinity of the gene were included (table 1;
see also UCSC Database, June 2002 Freeze; URL). Oligo-
nucleotides were designed by Primer Express 2.0 software
(ABI) adjusted to an annealing temperature of 55°C.
For PCR we used the 'tailed primer PCR' as described
before [7]. For amplification three oligonucleotides were
used: 1. tailed sense primer (tailed F), 2. anti-sense primer
and 3. labeled primer (labeled F) corresponding to the 5'-
tail sequence of tailed F. PCR conditions were as follows:
1 × PCR buffer (Qiagen), 1.5 pmol labeled F, 0.2 mM each
dNTP, 3 mM MgCl2, 0.2 pmol tailed F, 1.5 pmol reverse
primer, 0.25 U Qiagen Hot Start Taq (Qiagen) and 50 ng
DNA.
Electrophoreses were run using ABI standard protocols.
Raw data were analyzed by the Genotyper software (ABI)
producing a marker-specific allele image profile (AIP, see
[21] and [7]). AIP consists of series of peaks with different
heights reflecting the allele frequency within each ana-
lyzed DNA pool.
Statistics for comparisons of allele frequencies of patients
and controls was performed as described before [[21] and
[7]]. Case and control distributions were compared statis-
tically by means of contingency tables.
SSCP, sequencing and PCR/RFLP analyses
Exons 11, 12, 13 and 27 were analysed by the SSCP
method. PCR was performed using oligonucleotides
reported before ([18], exon 27 corresponding to exon 26).
Heat-denaturated fragments were then separated by poly-
acrylamide gel electrophoresis under non-denaturating
conditions yielding specific band patterns for each of the
alleles. Results were visualized by autoradiography. Alle-
les of representative probes were determined by direct
DNA sequence analysis on a 377 ABI automatic sequencer
(ABI). Afterwards, variations were genotyped individually
by PCR/RFLP method with restriction enzymes specific for
the respective change (for details see table 2). The varia-
tion in exon 27 was individually genotyped by the SSCP
method.
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